AOD-9604 is a short hGH fragment studied for adipocyte lipolysis; semaglutide is a long-acting GLP-1 receptor agonist. A structural, in-vitro mechanism comparison for NZ research.
AOD-9604 vs semaglutide compares two structurally unrelated research peptides that are sometimes confused because both appear in adipocyte-metabolism literature. AOD-9604 is a short human-growth-hormone fragment studied for adipocyte lipolytic signalling. Semaglutide is a long-chain GLP-1 receptor agonist studied for incretin-receptor pharmacology. They engage entirely separate receptor systems and are not comparable on a dose or potency basis.
AOD-9604 vs semaglutide: quick reference table
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Origin | hGH176-191 C-terminal fragment | Synthetic GLP-1 analog |
| Length | 17 residues | 31 residues |
| Average mass | ~1815 Da | ~4113.6 Da |
| Pathway/receptor studied | Adipocyte β3-adrenergic-like signalling | GLP-1 receptor |
| Structural feature | Intramolecular disulfide bridge | C18 diacid, Lys26 acylation |
Mechanistic differences
- AOD-9604 does not activate the classical growth-hormone receptor or the GLP-1 receptor in published binding assays.
- Semaglutide is selective for the GLP-1 receptor and is not studied for adipocyte β3-adrenergic-like signalling.
- AOD-9604 research typically uses adipocyte culture models (e.g. 3T3-L1); semaglutide research typically uses GLP-1R-transfected reporter cell lines.
- Because the two peptides act on entirely separate pathways, they are not interchangeable reference ligands in a receptor-pharmacology panel.
In-vitro assay comparison
| Assay focus | AOD-9604 | Semaglutide |
|---|---|---|
| Model system | Adipocyte culture | GLP-1R-transfected cell line |
| Primary readout studied | Glycerol release / lipolysis rate | cAMP accumulation (EC50) |
| Off-target checks | hGH-R activation, IGF-1 induction | GIP-R, glucagon-R cross-activity |
Certificate of analysis expectations
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Sourcing AOD-9604 and semaglutide in New Zealand
Kiwi Peps supplies both AOD-9604 and semaglutide to the KP-99 Purity Standard (99%+ HPLC-MS), with batch records in The Batch Book and Bench-Ready Dispatch nationwide. Strictly for in-vitro research use only.
Frequently asked questions
Are AOD-9604 and semaglutide comparable compounds?
No. They are structurally unrelated and engage separate pathways — AOD-9604 is studied for adipocyte lipolytic signalling, semaglutide for GLP-1 receptor pharmacology.
How do the molecular weights compare?
AOD-9604 is approximately 1815 Da across 17 residues; semaglutide is approximately 4113.6 Da across 31 residues.
Which is used for GLP-1 receptor assays?
Semaglutide is the appropriate reference ligand for GLP-1 receptor assays. AOD-9604 does not engage the GLP-1 receptor.
How does Kiwi Peps verify purity for both peptides?
Every batch is tested to the KP-99 Purity Standard (99%+ HPLC-MS) with results in The Batch Book.
